11 Jan 2019 Research

Myelofibrosis: Finding new ways to treat patients

Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.

Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.

Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.

The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.

Related posts

Cost of Living with Leukaemia Fund launches

16 November 2022

Cost of Living with Leukaemia Fund launches

Leukaemia Care and Leukaemia UK have launched a new financial support service, the Cost of Living with Leukaemia Fund, in response to the cost of living crisis in the UK….

Beloved actor who beat leukaemia now fronting charity TV ad to help raise vital funds

19 December 2023

Beloved actor who beat leukaemia now fronting charity TV ad to help raise vital funds

83-year-old actor Richard Tate will appear on screens from 26th December onwards to support Leukaemia UK’s call for legacy pledges (otherwise known as gifts in Wills), after surviving leukaemia thanks…

Leukaemia UK appoints Ian McCafferty CBE as their new Chair of Trustees to support new strategy to stop leukaemia devastating lives

7 November 2022

Leukaemia UK appoints Ian McCafferty CBE as their new Chair of Trustees to support new strategy to stop leukaemia devastating lives

Ian McCafferty CBE will take up the role in January 2023, from current Chair of Trustees, Chris Corbin OBE, and will lead the charity as it continues to grow. Chris…

A decade on: Dr Javier Redondo Muñoz continues to shape the future of Leukaemia research

18 May 2026

A decade on: Dr Javier Redondo Muñoz continues to shape the future of Leukaemia research

Ten years after joining the second cohort of Leukaemia UK’s John Goldman Fellowships (JGF), Dr Javier Redondo Muñoz is continuing to shape the future of leukaemia research. Now leading his own team in…